127 related articles for article (PubMed ID: 15679265)
1. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
2. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
[TBL] [Abstract][Full Text] [Related]
3. Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; McCosar BH; Weimar WR; Brittenham GM; Smith RE
J Med Chem; 1999 Jul; 42(13):2432-40. PubMed ID: 10395484
[TBL] [Abstract][Full Text] [Related]
4. Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
Bergeron RJ; Wiegand J; McManis JS; Bussenius J; Smith RE; Weimar WR
J Med Chem; 2003 Apr; 46(8):1470-7. PubMed ID: 12672247
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
[TBL] [Abstract][Full Text] [Related]
7. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
Bergeron RJ; Bharti N; Wiegand J; McManis JS; Singh S; Abboud KA
J Med Chem; 2010 Apr; 53(7):2843-53. PubMed ID: 20232803
[TBL] [Abstract][Full Text] [Related]
8. ICL670A: preclinical profile.
Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
[No Abstract] [Full Text] [Related]
9. Drug evaluation: Deferitrin for iron overload disorders.
Barton JC
IDrugs; 2007 Jul; 10(7):480-90. PubMed ID: 17642018
[TBL] [Abstract][Full Text] [Related]
10. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
[TBL] [Abstract][Full Text] [Related]
11. The design, synthesis, and evaluation of organ-specific iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2006 Nov; 49(24):7032-43. PubMed ID: 17125256
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
13. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC
IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
[TBL] [Abstract][Full Text] [Related]
15. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron RJ; Wiegand J; Bharti N; McManis JS
J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
[TBL] [Abstract][Full Text] [Related]
16. Desferrithiocin analogues and nephrotoxicity.
Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
J Med Chem; 2008 Oct; 51(19):5993-6004. PubMed ID: 18788724
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine in a Cebus apella primate model.
Bergeron RJ; Merriman RL; Olson SG; Wiegand J; Bender J; Streiff RR; Weimar WR
Cancer Res; 2000 Aug; 60(16):4433-9. PubMed ID: 10969789
[TBL] [Abstract][Full Text] [Related]
18. Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Park JH; Eiler-McManis E; Bergeron J; Brittenham GM
J Med Chem; 2005 Feb; 48(3):821-31. PubMed ID: 15689166
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships among desazadesferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
[TBL] [Abstract][Full Text] [Related]
20. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
